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PPRE-CLINICAL RESEARCH
Intramyocardial Injection of Autologous
Cardiospheres or Cardiosphere-Derived Cells Preserves
Function and Minimizes Adverse Ventricular Remodeling
in Pigs With Heart Failure Post-Myocardial Infarction
Shuo-Tsan Lee, MD,* Anthony J. White, MBBS, PHD,* Satoshi Matsushita, MD, PHD,*
Konstantinos Malliaras, MD,* Charles Steenbergen, MD,† Yiqiang Zhang, PHD,*
Tao-Sheng Li, MD, PHD,* John Terrovitis, MD,* Kristine Yee, DVM,* Sinan Simsir, MD,*
Raj Makkar, MD,* Eduardo Marba´n, MD, PHD*
Los Angeles, California; and Baltimore, Maryland
Objectives The purpose of this study was to test the safety and efficacy of direct injection of cardiosphere-derived cells
(CDCs) and their 3-dimensional precursors, cardiospheres, for cellular cardiomyoplasty in a mini-pig model of
heart failure after myocardial infarction.
Background Intracoronary administration of CDCs has been demonstrated to reduce infarct size and improve hemodynamic indexes in
the mini-pig model, but intramyocardial injection of CDCs or cardiospheres has not been assessed in large animals.
Methods Autologous cardiospheres or CDCs grown from endomyocardial biopsies were injected through thoracotomy
4 weeks after anteroseptal myocardial infarction. Engraftment optimization with luciferase-labeled CDCs guided
the choice of cell dose (0.5 million cells/site) and target tissue (20 peri-infarct sites). Pigs were randomly allo-
cated to placebo (n  11), cardiospheres (n  8), or CDCs (n  10). Functional data were acquired before injec-
tion and again 8 weeks later, after which organs were harvested for histopathology.
Results Beyond the immediate perioperative period, all animals survived to protocol completion. Ejection fraction was equiva-
lent at baseline, but at 8 weeks was higher than placebo in both of the cell-treated groups (placebo vs. CDC, p 
0.01; placebo vs. cardiospheres, p  0.01). Echocardiographic and hemodynamic indexes of efficacy improved dis-
proportionately with cardiospheres; likewise, adverse remodeling was more attenuated with cardiospheres than with
CDCs. Provocative electrophysiologic testing showed no differences among groups, and no tumors were found.
Conclusions Dosage-optimized direct injection of cardiospheres or CDCs is safe and effective in preserving ventricular function in
porcine ischemic cardiomyopathy. Although CDCs and cardiospheres have equivalent effects on left ventricular ejec-
tion fraction, cardiospheres are superior in improving hemodynamics and regional function, and in attenuating ven-
tricular remodeling. (J Am Coll Cardiol 2011;57:455–65) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.07.049i
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hardiac failure secondary to myocardial infarction (MI) is a
ajor public health problem. Left ventricular (LV) dysfunc-
ion after MI is an important predictor of subsequent
utcome (1), and although therapy has improved markedly
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he studies herein. All other authors have reported that they have no relationships to disclose.
rs. Lee, White, Matsushita, and Malliaras contributed equally to this work.c
Manuscript received May 2, 2010; revised manuscript received July 20, 2010,
ccepted July 27, 2010.n the past 30 years, the mortality and morbidity of ischemic
ardiomyopathy remain unacceptably high (2). Conse-
uently, cell therapy is under active investigation as a
otential therapeutic modality after MI. An effective cell
See page 466
herapy would offer patients a regenerative treatment option in
ddition to the currently available pharmacological and device
ptions. Autologous sources of cells are of particular interest
ecause immunologic rejection is avoided. Intracoronary infu-
ion of autologous bone marrow–derived mononuclear cells
as been evaluated in phase II clinical trials (3,4), but routine
linical use has not gained regulatory approval.
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Intramyocardial Cell Injection Is Safe and Effective January 25, 2011:455–65Cardiosphere-derived cells (CDCs)
are a heterogeneous mix of cells ex-
panded from cardiac tissue, with for-
mation of self-assembling spherical
clusters of heart-derived cells (i.e.,
cardiospheres) as an intermediate
processing step (5,6). CDCs are
clonogenic and exhibit multilin-
eage potential (7), thus fulfilling
key criteria for cardiac stem cells,
and they can be readily and reliably
expanded from tiny specimens of
heart muscle: Smith et al. (6)
found that 20 mg human heart
samples yielded 1.5 million
DCs on average within 45 days. Because endogenous regen-
ration of cardiomyocytes at a rate of about 1% to 2% per year
as been demonstrated in humans (8), and because CDCs are
re-programmed to differentiate into cardiac lineages, they
epresent a logical cell candidate for therapeutic testing.
Direct injection of CDCs in small animal models has
een shown to improve cardiac function in the setting of
xperimental MI (6,9,10), but data from large-animal mod-
ls are lacking. Coronary infusion of CDCs in pigs reduces
elative infarct size and improves hemodynamic indexes, but
V ejection fraction (LVEF) is not affected (11). Cardio-
pheres (50 to 200 m in diameter) would be expected to
mbolize at the arteriolar level, and thus are not well suited
or intracoronary administration. Nevertheless, direct head-
o-head comparison in a small-animal model has revealed
uperior benefits of cardiospheres relative to CDCs when
oth are delivered by intramyocardial injection (12). Thus, 2
uestions remain to be addressed in a clinically relevant
arge animal model: 1) Is direct injection superior to
ntracoronary delivery? 2) Are cardiospheres more effective
han CDCs?
Abbreviations
and Acronyms
ANOVA  analysis of
variance
CDC  cardiosphere-
derived cell
Emax  end-systolic
elastance
IV  intravenous
LV  left ventricular
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
Figure 1 Study Protocols
(A) 24-h engraftment study design (n  7). (B) Pivotal randomized, blinded, place
cardiospheres n  8, cardiosphere-derived cells [CDCs] n  10). Cath  catheterHere, we tested the safety and efficacy of intramyocardial
njection of cardiospheres and of CDCs in a mini-pig model
f ischemic cardiomyopathy. We first sought to quantify
nd optimize the engraftment of CDCs when injected
irectly into myocardium, and then to assess the safety and
fficacy of the optimized dose of CDCs (and, by compari-
on, cardiospheres) in improving cardiac function.
ethods
tudy design. The current studies were performed in 2
arts. Study 1 (Fig. 1A) consisted of open-label experiments
o quantify engraftment 24 h after intramyocardial CDC
njection in the porcine MI model. The engraftment data
ere used to inform the dosage and target tissue of injection
f CDCs for study 2, which was a pivotal placebo-
ontrolled, blinded randomized study of safety and efficacy
f either cardiosphere or CDC direct intramyocardial injec-
ion (Fig. 1B). Animals were randomly allocated to receive
ither placebo or 10 million cells in cardiosphere or CDC
orm, administered as 20 injections of 0.5 million per site.
he dose of 10 million cells was chosen on the basis of the
ngraftment data from study 1, which had demonstrated the
ighest percentage engraftment of cells occurred when a
maller number was injected at each site in the peri-infarct
order zone. Cells or placebo were injected under direct
isualization by open-chest surgery performed 4 weeks after
I. The pigs were then followed for 8 more weeks, to assess
afety and efficacy.
reation of MI and acquisition of ventricular biopsy
pecimens. General anesthesia was induced in adult female
ucatan mini-pigs by intramuscular ketamine 20 mg/kg,
cepromazine 0.25 mg/kg, and atropine 0.05 mg/kg, fol-
owed by 10 ml intravenous (IV) thiopental. Endotracheal
ntubation was then performed, and anesthesia maintained
y ventilation with 1% to 2% isoflurane. Under sterile
trolled study design (placebo n  11,
; echo  echocardiography; MI  myocardial infarction.bo-con
ization
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January 25, 2011:455–65 Intramyocardial Cell Injection Is Safe and Effectiveonditions, the mini-pigs were subjected to an anteroseptal
I by inflation of an angioplasty balloon in the mid-left
nterior descending artery to cause coronary occlusion for
.5 h. Catheters were inserted through the left carotid
rtery. Ventricular tachycardia and/or ventricular fibrillation
equiring external cardioversion were very common, despite
dministration of 50 mg IV amiodarone, and additional 50
g boluses of IV amiodarone to a maximum of 200 mg if
requent ventricular premature beats were seen. There was
n overall mortality of 34% associated with creation of the
I in these studies.
After reperfusion, during the same episode of general
nesthesia, 4 to 6 right ventricular biopsies were obtained
sing a standard clinical cardiac bioptome introduced
hrough the right internal jugular vein. The biopsies were
mmediately placed into ice-cold cardioplegia solution
Ca and Mg-free PBS with 5% dextrose, mannitol
8.6 mmol/l, KCl 1.6 mmol/l, NaHCO3 3.1 mmol/l, and
eparin), and cardiospheres or CDCs were grown from
hese biopsy samples.
rowth of cardiospheres and CDCs. The CDCs were
ultured according to published protocols (5,6). Briefly, cardiac
iopsy specimens (10 to 40 mg) were minced, and subjected to
ollagenase IV digestion. These explants were plated onto
bronectin-coated plastic plates with cardiac explant medium
Iscove’s Modified Dulbecco’s Medium [Invitrogen, Carlsbad,
alifornia], 20% FBS, 1% penicillin-streptomycin, 1%
-glutamine, 0.1 mM 2-mercaptoethanol). A monolayer of
dherent cells grew out from the biopsy, which was harvested
fter 1 to 2 weeks. The harvested outgrowth was replated onto
oly-D-lysine–coated wells. Under these conditions, within
to 5 days, the majority of the cells gave rise to free-floating
lusters of cells, termed cardiospheres. In a third phase, the
dherent cells were discarded, and the floating cardiospheres
ere collected and plated once again onto fibronectin-coated
ellware. The cardiospheres adhered and flattened to form a
onolayer of cells referred to as CDCs, which were passaged
s they became confluent.
So-called “secondary cardiospheres” were used in the in
ivo experiments, meaning that an equivalent number of
DCs (10 million) were harvested and counted, then plated
ack into poly-D-lysine–coated wells where they formed
ardiospheres for a second time, which were injected into
he animals. The exact number of cells may have actually
een higher than 10 million (due to further proliferation
fter counting), or lower than 10 million (due to adherence
f some cells to the plastic), but this estimation was used to
ompare “equivalent” numbers of cells in the cardiosphere
nd CDC groups.
abeling and detection of injected CDCs for engraftment
tudies. Cultured cells were transduced at the outgrowth
tage with a lentiviral vector encoding the firefly luciferase
ene, and further processed to create CDCs. Seven animals
hat had undergone the MI and right ventricle biopsy
rotocols received intramyocardial injection of 0.5 million, c.0 million, or 10 million CDCs per injection site in
ntrainfarct, peri-infarct (borderzone), or remote normal
entricular locations. The animals were sacrificed 24 h later
or assessment of cell engraftment, as described (11).
A standard curve was constructed by measuring the
uciferase signal from known numbers of transduced CDCs
piked into homogenized cardiac tissue. A standard curve
pecific for each batch of cells needed to be constructed
ecause of variation of transduction efficiency with each
atch. The injected cardiac tissue was then homogenized
nd analyzed for luciferase signal, which was converted to
ell number by reference to the standard curve. Off-target
xpression of luciferase in lungs, liver, spleen, and kidneys
as quantified in a similar manner. This is a validated
ethod with high sensitivity and reproducibility (11,13,14).
ivotal study. INTRAMYOCARDIAL INJECTION OF
XPERIMENTAL TREATMENT BY OPEN CHEST SURGERY.
hirty-three pigs had general anesthesia induced a second
ime, 4 weeks after MI, with the same drugs. The LVEF
as measured by contrast ventriculography, with the image
ntensifier in the 60° right anterior oblique position. If the
VEF was55%, then the pig was deemed to have had too
mall of an MI and was excluded from the study. That
pplied to 1 animal. Intramyocardial direct injection was
erformed by open-chest surgery under sterile conditions.
ternotomy was performed and the pericardium opened to
xpose the heart. Twenty intramyocardial injections of
ither cardiospheres (0.5 million cells suspended in 0.1 ml
er injection), CDCs (0.5 million cells suspended in 0.1 ml
er injection), or placebo (0.1 ml of phosphate buffered
aline alone) were performed into the beating heart, using a
-ml tuberculin syringe and 26-G needle. The injections
ere spaced around the perimeter of the macroscopically
isible infarct scar, approximately 1 cm from the gross
order. With the exception of 3 procedure-related periop-
rative complications (1 episode of catheter-related ventric-
lar tachycardia, 1 punctured lung, 1 cardiogenic shock), all
nimals survived after surgery and completed the protocol;
hus, post-procedure mortality was nil. This resulted in
9 pigs in the final analysis: n  11 allocated to receive
lacebo (vehicle alone), n  8 allocated to receive cardio-
phere injections, and n  10 allocated to receive CDC
njections.
ssessments of LV structure and function. Contrast left
entriculography was performed using a pigtail catheter,
ith injection of 30 ml of iodinated contrast (Omnipaque,
E Healthcare, Princeton, New Jersey) at 15 ml/s. We
ound that transthoracic echocardiography was inadequate
o image the cardiac apex; instead, epicardial echocardiog-
aphy (Aspen, Acuson Corp., Mountain View, California)
as performed while the chest was open, by placement of a
-MHz ultrasound probe into a sterile sleeve, and direct
lacement of the probe on the epicardial surface of the
eart. The LV chamber size and ejection fraction were
alculated by tracing the endocardial border during systole
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Intramyocardial Cell Injection Is Safe and Effective January 25, 2011:455–65nd diastole in apical 4-chamber and apical 2-chamber
iews. Measurements of the LV septal wall were made in
he apical 4-chamber view. Basal septal measurements were
ade adjacent to the mitral valve leaflet insertion. Apical
eptal measurements were made at the junction of the apical
ne-third and basal two-thirds of the septum, at the
eri-infarct position. These data were used to compare
hickness and systolic thickening of the septum. Impedance
atheter measurements (Millar Instruments, Houston,
exas) were used to acquire simultaneous LV pressure and
olume measurements, allowing derivation of multiple in-
exes of systolic and diastolic LV function.
erminal evaluation. The terminal evaluation in the piv-
tal protocol further included an electrophysiologic study
ith provocative testing to examine inducibility of ventric-
lar tachycardia, followed by euthanasia and histopathology
f heart, lung, liver, spleen, kidneys, and brain.
enetic labeling and later detection of injected CDCs.
lease refer to the Online Appendix for these methods and
esults.
tatistical analysis. Data are presented in tables as mean
D, and in graphs as mean  SEM. Statistical analyses
ere performed in SPSS version 17 for Windows (SPSS
nc., Chicago, Illinois). For comparison of the 3 treatment
roups, first Levene’s test for equality of variances was
erformed. If the null hypothesis was accepted, the vari-
nces were assumed to be similar, and the 3 groups were
ompared by 1-way analysis of variance (ANOVA). Only if
he ANOVA was found to be significant were post-hoc
omparisons between groups performed by the method of
east-significant difference. If Levene’s test had a p value
0.05, a difference in variances between the groups was
ssumed and the nonparametric Kruskal-Wallis test was
sed, followed by post-hoc comparison by Dunn’s test. This
onparametric comparison only needed to be used for
variables: final end-systolic elastance (Emax), LVEF by
chocardiography at baseline, and delta heart rate. All
values 0.05 were deemed significant for ANOVA,
ruskal-Wallis, and post-hoc comparisons.
esults
reation of the model. Five of 12 animals died during
reation of MI in the engraftment studies, and 15 of 47
nimals died during creation of MI in the pivotal study, giving
n overall mortality rate of 34% associated with creation of MI
n the 2 studies. With the exception of 3 acute procedure-
elated perioperative complications (1 episode of catheter-
elated ventricular tachycardia, 1 punctured lung, 1 cardiogenic
hock), all animals that received intramyocardial injections
urvived to complete the study protocol.
ngraftment studies. Autologous, luciferase-labeled CDCs
0.5 million, 2 million, or 10 million per site) were injected,
ither into the area of infarction, the peri-infarct border zone,
r remote normal myocardium. Each dose was tested in 2 to 7 lnimals, with individual animals receiving multiple anatom-
cally marked injections of different dosages to minimize
nimal use. Twenty-four hours later, the animals were sacri-
ced and the hearts (and other organs) were removed to assess
hort-term engraftment. Myocardial tissue samples were taken
rom the injection target areas, and from off-target organs
lungs, liver, spleen, kidneys). Within the heart, injection into
he scarred infarcted area yielded no surviving cells at any
njected dosage (Fig. 2). In contrast, 8% to 9% of injected
DCs survive at 24 h after injection into remote normal
yocardium, regardless of dosage. In the peri-infarct border
one, engraftment was inversely related to the number of cells
njected, being 8%, 1.8%, and 0.1% of the 0.5 million,
million, and 10 million doses, respectively.
On the basis of these results, we chose the lowest dose of 0.5
illion cells per site for the pivotal studies. The results of the
ngraftment studies are consistent with previous similar stud-
es, none of which have described engraftment greater than
0% at 24 h (14). It is possible that a dose even lower than 0.5
illion cells per site would result in higher percentage engraft-
ent, but in this series the lowest dose tested was 0.5 million
er site. In addition, given that cardiac stem cells have little
ong-term survival advantage in normal myocardium (15), and
hat they seem not to engraft at all when injected directly into
n area of myocardial infarction, we targeted the peri-infarct
one in the pivotal study. It is also known that engraftment is
ery low at 8 weeks relative to acute engraftment (9,16), so
Figure 2 Engraftment of CDCs 24 h
After Intramyocardial Injection
When injected into the infarct scar, no cardiosphere-derived cells (CDCs) are
detectable 24 h later. When injected into remote normal myocardium, approxi-
mately 8% to 9% of each dose of injected cells remains in situ and viable.
When injected into the peri-infarct border zone, the proportion of cells surviving
is inversely proportional to the number of cells injected; 0.5 million (open
bars), 2.0 million (gray bars), and 10.0 million (solid bars) indicate the num-
ber of cells injected into myocardium at each site.uciferase was not used in the long term studies; instead, lacZ
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January 25, 2011:455–65 Intramyocardial Cell Injection Is Safe and Effectiveabeling was used in a subset of the CDC-treated animals in
he longer pivotal study.
Quantification of off-target expression at 24 h revealed no
easurable cells in liver, spleen, or kidney, but 0.9% of
njected CDCs could be detected in the lungs (see Supple-
entary Table 1). This is 10-fold lower than the engraft-
ent seen in the target myocardium. These data are
onsistent with recent findings that many directly injected
ells wash away through coronary veins before they are able
o “stick” in the myocardium (9,17); the percentage retained
n the heart can be increased by iron-loading cells and
pplying an apical magnet (9), an approach that we did not
se here but which merits further investigation.
ivotal placebo-controlled study. On the basis of the 24 h
ngraftment data, a dosage of 0.5 million CDCs (or an
quivalent cell number of cardiospheres) per site was selected,
nd direct intramyocardial injections performed in 20 peri-
nfarct sites, giving a total cell dosage of 10 million CDCs.
umerically coded loaded syringes were provided to the
urgeon, who was blinded as to group assignment (as were all
ther investigators) until completion of all protocols and data
nalysis. It is possible that the surgeon may have been able to
ecognize whether he was injecting a cell suspension or vehicle
lone because of the turbidity of cell suspensions. However,
urgeons did not communicate any suspicions to the rest of the
eam, and they did not analyze any of the data.
Figure 3 shows the LVEF data derived from contrast
entriculography. The LVEF at baseline was equivalent in
he 3 groups. Figure 3B also demonstrates that, 8 weeks
fter injection, the LVEF was significantly higher than
lacebo in both of the cell-treated groups (ANOVA p 0.02;
lacebo vs. CDCs p  0.01, placebo vs. cardiosphere
 0.01), whereas there was no significant difference in
nal LVEF between the CDC group and the cardiosphere-
reated group. Figure 3C shows that the treatment effect
final minus baseline LVEF) was significantly higher than
chocardiographic IndexesTable 1 Echocardiographic Indexes
Placebo
(n  9)
CDC
(n  9)
CSph
(n  5
Ejection fraction, %
Baseline 43 7 44 12 43 5
Final 40 7 47 5 44 5
Treatment effect (delta) 3 11 3 10 1 5
Systolic volume, ml
Baseline 29.5 4.8 24.7 5.0 31.4 3
Final 40.5 11.8 34.7 7.2 31.8 5
Treatment effect (delta) 10.9 13.2 10.0 6.2 0.4 5
Diastolic volume, ml
Baseline 52.0 9.4 44.2 5.3 55.6 9
Final 66.1 12.9 65.0 10.7 56.2 7
Treatment effect (delta) 14.0 15.0 20.8 10.1 0.7 8
Baseline ejection fraction did not exhibit homogeneity of variance between groups, so the Krusk
CDC  cardiosphere-derived cells; CSph  cardiospheres.lacebo in both of the cell-treated groups (ANOVA s 0.002; placebo vs. CDC p  0.001, placebo vs.
ardiosphere p 0.01). Echocardiographic measurement of
VEF yielded qualitatively similar differences in final
VEF and delta LVEF measurements, although the differ-
nces between the groups were not statistically significant by
his modality (Table 1). Echocardiographic measurement
id, however, demonstrate progressive ventricular dilation
n placebo and CDC groups, which was attenuated in the
ardiosphere-treated animals (Fig. 4B, Table 1). Baseline
ystolic and diastolic LV volume measurements were ran-
omly lower in the CDC-treated animals (Table 1).
In addition, echocardiography revealed that final mea-
urements of LV septal wall thickness were increased in
oth of the cell-injected groups relative to placebo (Fig. 5B).
he thickening fraction of the apical septum was also
ncreased in cardiosphere-injected pigs (Fig. 5C), adding to
he evidence that cardiospheres have an efficacy advantage
ver CDCs. These salutary changes indicate improved
orphology and function in the infarct region with autol-
gous CDC or cardiosphere injections.
Table 2 and Figure 4A outline the results of LV pressure-
olume loop analysis. Most measurements were made at
teady state. However, one important measurement, Emax,
as derived, by definition, as the slope of the end-systolic
ressure-volume relationship from the family of loops pro-
uced during balloon occlusion of the inferior vena cava
18,19) (Fig. 4A). The Emax is a rigorous load-independent
easure of contractility. Final Emax in the cardiosphere
roup was higher than in placebo-treated pigs, indicating
mproved LV contractility in these animals (placebo 1.03 
.29 mm Hg/ml, CDC 1.66  0.45 mm Hg/ml, cardio-
phere 3.16  1.32 mm Hg/ml; Kruskal-Wallis p  0.003;
lacebo vs. CDC p  NS, placebo vs. cardiosphere
 0.03, cardiosphere vs. CDC p  not significant). The
max in the CDC group tended to increase but was not
p Values
ANOVA Placebo vs. CDC Placebo vs. CSph CDC vs. CSph
0.98* — — —
0.07 — — —
0.39 — — —
0.04 0.04 0.49 0.02
0.21 — — —
0.13 — — —
0.04 0.054 0.44 0.02
0.27 — — —
0.02 0.25 0.06 0.01
s test was performed instead of analysis of variance (ANOVA).)
.9
.6
.4
.8
.8
.5ignificantly higher than in placebo-treated animals.
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Intramyocardial Cell Injection Is Safe and Effective January 25, 2011:455–65Steady-state hemodynamics showed few differences
Table 2) except for a greater fall in LV end-diastolic
ressure in the cardiosphere-treated group (Fig. 4C). Taken
ogether with the lesser increase of end-diastolic volume in
his group, cardiosphere-injected animals experience dispro-
ortionate benefit with regard to attenuation of adverse
entricular remodeling relative to the other 2 groups (CDCs
r placebo).
ndicators of safety. Ventricular tachycardia was readily
nducible by application of programmed extrastimuli in all
nimals before sacrifice, consistent with previous reports
11,20). However, there were no deaths (sudden or otherwise)
n either group after the immediate periprocedural period.
Post-mortem examination, with gross analysis as well as
istology of heart, brain, kidney, lung, liver, and spleen
Table 3), detected no tumors 8 weeks after intramyocardial
Figure 3 Intramyocardial Injection of Cardiospheres or CDCs R
(A) Left ventricular ejection fraction (LVEF) by ventriculography is shown for each a
error bars. The LVEF in the placebo group deteriorated significantly (p  0.01) whe
cardiosphere-derived cell. (B) The LVEF did not differ between placebo group (ope
(analysis of variance [ANOVA] p  0.63); however, by the conclusion of the study,
group (ANOVA p  0.02; placebo vs. CDCs p  0.01, placebo vs. cardiosphere p
the final measurement. (C) The treatment effect (final minus baseline LVEF) was s
significantly different from placebo. Each solid circle represents 1 animal; the squnjection of CDCs or cardiospheres. hong-term CDC engraftment. Fluorescence immuno-
istochemistry in the 2 animals with lacZ CDCs,
evealed the presence of labeled cells 8 weeks after
njection. Supplementary Figure 1 shows 2 examples of
slands of cardiomyocytes with lacZ-positive nuclei in the
eri-infarct zone, 1 from each animal that received
ntramyocardial genetically labeled CDCs. This finding
stablishes that a proportion of injected autologous
DCs, or their progeny, which will also be labeled by this
ntegrating vector, persists for 8 weeks within the border
one of infarcted myocardium. However, the current
ethodology does not clarify whether the lacZ cardio-
yocytes have occurred through differentiation of the
njected CDCs, or by fusion of the injected CDCs with
esident cardiomyocytes. We did not perform lacZ label-
ng in any of the cardiosphere-injected animals, but we
in Significant Improvement of LVEF Relative to Placebo
at baseline and final measurements (lines), with mean shown as squares with
either of the cell-treated groups deteriorated (p  not significant [NS]). CDC 
), cardiosphere group (red bars), or CDC-treated group (green bars) at baseline
ell-treated groups had a significantly higher LVEF compared with the placebo
1). The 2 cell-treated groups were not statistically different from each other at
antly different between groups (ANOVA p  0.002), with both cell-treated groups
ith error bars represent the mean treatment effect for each group.esults
nimal
reas n
n bars
both c
 0.0
ignific
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earts (12). In addition, these labeling studies do not
nform the relative contributions of direct regeneration
ersus indirect (paracrine) effects on the efficacy end
oints, although we have found that both mechanisms
lay a role in post-MI mice injected with human
DCs (16).
iscussion
he present study is notable for the rational selection
rocess for the dose and location of cell injections to be
ested; the randomized, blinded, and placebo-controlled
esign; and the head-to-head comparison of 2 promising
Figure 4 Multiple Indexes Reveal That Cardiosphere Administra
(A) The end-systolic elastance (Emax) was significantly higher in the cardiosphere g
diosphere-derived cell (CDC) group (red bars) was not significantly higher than tha
cebo vs. CDC p  NS; placebo vs. cardiosphere p  0.03). Representative familie
(B) Delta diastolic volume (final end-diastolic volume [EDV] minus baseline EDV) is
treated group (red bar), with a trend to being lower than in the placebo group (wh
(EDP) measurements demonstrated a significantly higher fall in EDP in cardiosphe
spheres vs. CDCs p  0.001). This finding indicates that the ventricles of cardios
CDC group (red bar) and placebo group (white bar).eart-derived cell products that can be readily grown mrom percutaneous biopsies. The data reveal that direct
urgical injection of autologous cardiospheres or CDCs
ffectively halts the deterioration in LVEF after a large
yocardial infarction, compared to a 7% absolute reduc-
ion in LVEF over 8 weeks of observation in placebo-
reated animals. Although cell treatment did not increase
he LVEF relative to baseline, the deterioration of the
lacebo group meant that the final LVEF was signifi-
antly better in either of the cell-injected groups than in
he placebo-injected group. If differences of this magni-
ude were translated to the clinical arena, this may well be
clinically meaningful benefit. For comparison, a meta-
nalysis of the effect of intracoronary infusion of bone
Is Superior to CDC Administration
green bars) than in the placebo-injected pigs (white bars). The Emax in the car-
cebo-treated animals. (Levene’s test p  0.05; Kruskal-Wallis p  0.003; pla-
V loops are shown (right) for placebo, CDC, and cardiosphere-treated animals.
ficantly lower in the cardiosphere-treated group (green bar) than in the CDC-
) also (analysis of variance [ANOVA] p  0.02). (C) Delta end-diastolic pressure
ted animals compared with CDC-treated animals (ANOVA p  0.01; cardio-
injected hearts (green bar) were coping better with the infarction than were thetion
roup (
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ontrols (4).
Cardiospheres, but not CDCs, also increased end-systolic
lastance and attenuated the ventricular dilation associated
ith myocardial infarction.
The engraftment data indicate that: 1) no cells survive
hen injected into the infarct scar; 2) short-term engraft-
ent is 8% regardless of injected cell dose in remote
ormal myocardium; and 3) in the infarct border zone,
less is more”: the percent survival at 24 h decreases
rogressively from 8% to 1% as dosage escalates. This
s the first description that proportional engraftment of
njected cells is improved by injection of lower cell doses
t each injection site. One interpretation of these results
s that survival in the border zone may be limited by the
enuously perfused, substrate-limited, peri-infarct envi-
onment. In this scenario, while the absolute number of
njected cells able to survive remains about the same,
ercentage survival of injected cells is greater with injec-
ion of lower numbers of cells per site. This discovery has
otential implications for trials of intramyocardial ad-
inistration of many other cell types, not only CDCs. In
ractical terms, we chose not to inject into normal
yocardium, as it is unclear whether cells thus injected
ould track into and influence remote sites of chronic
njury, and we avoided injection into the scar, given the
nding of no engraftment. We thus chose to inject the
eri-infarct area, and to use the lowest tested dose,
amely, 0.5 million cells per site, in each of 20 sites (a
umber chosen as a practical limit to achieve good
Figure 5 Echocardiography Reveals Improved Regional Contrac
(A) A representative apical 4-chamber epicardial echocardiography image. ANOVA
are increased in cardiosphere-derived cell (CDC)-injected pigs (red bars) and cardi
(C) Apical (peri-infarct) septal thickening is increased in cardiosphere-injected pigs
vs. cardiosphere group p  0.01). The red bar indicates CDC-injected pigs.overage of the border zone, rather than empirically). cThe preservation of global LVEF in cell-treated ani-
als, compared to the deterioration in the placebo group,
as not observed with intracoronary administration of
DCs in the same porcine model of MI (11). Thus,
ntramyocardial injection may represent a more effective
oute of administration than the intracoronary route (11).
e additionally find that cardiospheres are superior to
DCs in terms of hemodynamic benefit as well as in
ttenuation of adverse remodeling. Direct expansion of
esident cardiac stem cells from human specimens was
riginally described by Messina et al. (5), who collected
ardiac-derived cells and subcultured them as 3-dimensional
ell aggregates, which they dubbed cardiospheres. This
echnique was patterned from the neurosphere experience
21). The Marba´n laboratory adapted and miniaturized
he cardiosphere technique for utility with percutaneous
ndomyocardial biopsies as the tissue of origin, plating
ardiospheres in monolayer culture to yield therapeuti-
ally relevant numbers of CDCs (6). However, the
elative utility of cardiospheres versus CDCs was not
ntirely clear before the present study. Intriguing early
eports demonstrated that injection of small numbers of
ardiospheres effectively doubles LV fractional shorten-
ng after MI (5), as opposed to large numbers of
onolayer-cultured CDCs, providing a 64% increase in
he LVEF (6). Further, cardiosphere culture increased
he expression of c-kit, a stem cell marker, from 10% to
0% after 6 days of culture (5). Subsequent transition
rom cardiosphere to monolayer culture results in de-
reased c-kit expression (6). These results suggest that
ardiosphere culture might enhance the “stemness” of
in Cardiosphere-Injected Pigs Relative to Sham-Injected Controls
lysis of variance; LV  left ventricle. (B) Final measurements of septal thickness
e-injected pigs (green bars) relative to sham-injected controls (white bars).
n bar) relative to sham-injected controls (white bar) (ANOVA p  0.01; placebotility
 ana
ospher
(greeardiac-derived cells, and that the implantation of car-
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unction relative to monolayer-cultured cells (12). Such
peculation gains credence from the present findings that
ardiospheres are superior to CDCs in terms of hemo-
ynamics and ventricular remodeling.
Two recent reports have challenged the stem cell
haracteristics and cardiomyogenic potential of cardio-
pheres (22,23), and another has shown no demonstrable
unctional benefit and an absence of viable cardiac stem
ells 8 weeks after injection (24). Methodological varia-
ions can explain the negative findings in these reports
7,25). Experiments in our laboratory over the past 6
ears (flow cytometry, genetic lineage tracing, clonal cell
xpansion, and protocol optimization experiments) have
haracterized CDCs as a natural mixture of progenitor
nd support cells expanded from myocardial biopsy spec-
mens, with validated, reproducible growth characteris-
ics, clonogenicity and multilineage potential (6,7). The
unctional benefit of cells derived from cardiac biopsy
pecimens is also quite reproducible (6,9,10,12), despite
ow long-term engraftment rates of injected cells
9,14,16). The exact mechanism of functional benefit
ppears to involve an important, if not dominant, con-
ribution of indirect effects to boost angiogenesis and
Pressure-Volume Loop-Derived IndexesTable 2 Pressure-Volume Loop-Derived Index
Placebo (n  11) CD
Heart rate, beats/min
Baseline 121 12
Final 112 17
Treatment effect (delta) 9 16
Pmax, mm Hg
Baseline 97.0 11.5
Final 87.1 11.4
Treatment effect (delta) 9.9 12.9
LVEDP, mm Hg
Baseline 14.6 3.1
Final 12.6 3.7
Treatment effect (delta) 1.9 3.4
dP/dt max
Baseline 1,967 370 1
Final 1,589 446 1
Treatment effect (delta) 378 462 
dP/dt min
Baseline 1,984 480 1
Final 1,516 291 1
Treatment effect (delta) 468 600
Tau, ms
Baseline 39.84 4.87 3
Final 41.25 7.21 4
Delta 1.41 8.39 
*The delta heart rate variable did not exhibit homogeneity of variance b
of variance (ANOVA). †For further details about post-hoc comparisons
dP/dt max  maximum rate of rise of left ventricular pressure; dP/
ventricular end-diastolic pressure; Pmax  maximum pressure genera
relaxation; other abbreviations as in Table 1.ardiomyogenesis (16). hOpen-chest surgery would be unlikely to gain clinical
cceptance unless adjunctive to clinically indicated surgery;
owever, less invasive methods of intramyocardial administra-
ion, such as transendocardial catheter-mediated delivery, may
e more acceptable if this route were also shown to be
fficacious, as has been shown with mesenchymal stem cells
26).
The field is very cognizant of the potential for danger-
us side effects of cardiac cell therapy, such as teratoma
elated to embryonic stem cell (27) or induced pluripo-
ent stem cell (28) administration, or ventricular arrhyth-
ia related to skeletal myoblast administration (29). In
he context of these safety concerns, the absence of
umor, the equivalence of ventricular tachycardia induc-
bility in the control and treatment groups of the current
tudy, and the zero post-treatment mortality in the
resent study are reassuring. With regard to translation,
phase I-II clinical study of CDCs—the CADUCEUS
CArdiosphere-Derived aUtologous stem CElls to re-
erse ventricUlar dySfunction) study—is under way (30).
hat study utilizes CDCs delivered through the intra-
oronary route. The present findings motivate future
linical studies involving direct intramyocardial injection
f either CDCs or cardiospheres—with intriguing results
 10) Cardiospheres (n  7) ANOVA p Value
12 117 17 0.72
13 117 19 0.65
12 1 36 0.72*
6.9 93.8 14.6 0.13
10.4 86.2 8.1 0.90
11.2 7.9 16.0 0.14
5.1 18.0 5.3 0.20
6.2 12.1 4.1 0.19
4.4 5.8 1.7 0.01†
278 1,784 693 0.56
370 1,422 333 0.58
280 382 876 0.93
346 1,784 394 0.11
357 1,546 444 0.99
501 247 520 0.25
5.51 41.28 7.21 0.70
4.57 41.88 3.82 0.94
6.12 0.03 5.42 0.84
groups, so the Kruskal-Wallis test was performed instead of analysis
a LVEDP among the 3 groups, please refer to Figure 4C.
 the minimum rate of rise of left ventricular pressure; LVEDP  left
left ventricle during cardiac cycle; tau  measure of left ventriculares
C (n
119
109
9
86.9
88.4
1.5
14.5
16.0
1.5
,770
,430
340
,584
,527
56
8.93
0.92
1.98
etween
of delt
dt mininting that the latter may be preferable.
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